Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| PM Parabilis MedicinesCompany profile Develops medicines targeting historically undruggable protein targets in cancer Develops medicines targeting historically undruggable protein targets in cancer | $305M | Series FSeries C+ | Biotech | United States | Investors Alderline GroupARCH Venture Partners +21Catalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners | |
| NT Nocion TherapeuticsCompany profile Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. Nocion Therapeutics develops small-molecule therapies for conditions involving cough and itch. | $23M | Series B+Series B | Biotech | United States | Investors Undisclosed | |
| S STRM.BIOCompany profile Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy Develops non-viral gene delivery platform for in vivo cell engineering and gene therapy | $8M | Seed2Seed | Biotech | United States | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $50M | Series A | Biotech, Healthtech | United States | Investors | |
| MT Develops therapies to halt fibrosis in multiple organ systems | $76M | Series B | Biotech | United States | Investors | |
| PS Provides AI-native due diligence for life sciences dealmaking | $20M | Series A | Biotech | United States | Investors | |
| RM Rakuten MedicalCompany profile Develops and commercializes Alluminox platform-based photoimmunotherapy for cancer treatment Develops and commercializes Alluminox platform-based photoimmunotherapy for cancer treatment | $100M | Series FSeries C+ | Biotech | United States | Investors | |
| CH Corsera HealthCompany profile Develops preventive RNAi medicines for cardiovascular disease prediction and prevention Develops preventive RNAi medicines for cardiovascular disease prediction and prevention | $80M | Series A | Biotech, Healthtech | United States | Investors | |
| ST Uses cells as sensors to uncover first-in-class medicines | $200M | Series CSeries C+ | Biotech | United States | Investors | |
| B BiographicaCompany profile Uses AI-driven discovery to develop next-generation crop traits and improve agricultural productivity and resilience Uses AI-driven discovery to develop next-generation crop traits and improve agricultural productivity and resilience | £7M | Undisclosed | Biotech, Agritech | United Kingdom | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →